Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 186 participants.

Also called NCT05213104

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 186 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05213104
  • EudraCT 2021-002608-10
Other papers using this trial's data
  • Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial Circulation, 2024-11-19 DOI, PubMed 39222035

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05213104. Randomized; single masking; primary purpose treatment. Start 2022-03-23 (actual); primary completion 2024-02-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
Acronym
AFLOAT
Condition
Patent Foramen Ovale
Condition
Atrial Arrhythmia
Condition
Cryptogenic Stroke
Intervention (Drug)
Flecainide
Intervention (Drug)
Flecainide
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Fonds de Dotation ACTION (class: other)

Record details

Record id
cardio:ct-nct05213104
Content hash
389140af8a07de0201a6503675083bbb6c8a442d689a90c21e05cb92445efcda